company background image
SIPH

Société des Industries Pharmaceutiques de Tunisie - BVMT:SIPHA Stock Report

Last Price

د.ت4.11

Market Cap

د.ت7.4m

7D

0%

1Y

n/a

Updated

30 Sep, 2022

Data

Company Financials +
SIPHA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

SIPHA Stock Overview

Société des Industries Pharmaceutiques de Tunisie - S.A.

Société des Industries Pharmaceutiques de Tunisie - Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Société des Industries Pharmaceutiques de Tunisie -
Historical stock prices
Current Share Priceد.ت4.11
52 Week Highد.ت6.12
52 Week Lowد.ت3.20
Beta0
1 Month Change27.64%
3 Month Changen/a
1 Year Changen/a
3 Year Change46.79%
5 Year Change-34.97%
Change since IPO-77.15%

Recent News & Updates

Shareholder Returns

SIPHATN PharmaceuticalsTN Market
7D0%-2.6%0.8%
1Yn/a-37.0%2.3%

Return vs Industry: Insufficient data to determine how SIPHA performed against the TN Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SIPHA performed against the TN Market.

Price Volatility

Is SIPHA's price volatile compared to industry and market?
SIPHA volatility
SIPHA Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement4.0%
Market Average Movement3.2%
10% most volatile stocks in TN Market5.3%
10% least volatile stocks in TN Market2.0%

Stable Share Price: Insufficient data to determine SIPHA's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine SIPHA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1970n/aAnis Klouzhttps://www.siphat.rns.tn

Société des Industries Pharmaceutiques de Tunisie - S.A. engages in the research, development, manufacture, packaging, and marketing of pharmaceutical products for human use in Tunisia and internationally. The company offers products in the areas of allergology, analgesics, anesthesia, antihypertensive, antispasmodics, cardiology and angiology, cardiovascular system, dermatology, gastroenterology, hepatology, infectiology, metabolism and nutrition, neurology, pneumology, rheumatology, and stomatology, as well as anti-inflammatory drugs. It produces drugs of various galenic formulations in the form of tablets, capsules, sachets, tubes, suppositories, drinkable phials, perfusable bags, flasks, litters of concentrated solutions, perfusable solution bottles, and injectable ampoules.

Société des Industries Pharmaceutiques de Tunisie - Fundamentals Summary

How do Société des Industries Pharmaceutiques de Tunisie -'s earnings and revenue compare to its market cap?
SIPHA fundamental statistics
Market Capد.ت7.40m
Earnings (TTM)-د.ت14.52m
Revenue (TTM)د.ت24.40m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SIPHA income statement (TTM)
Revenueد.ت24.40m
Cost of Revenueد.ت15.38m
Gross Profitد.ت9.03m
Other Expensesد.ت23.55m
Earnings-د.ت14.52m

Last Reported Earnings

Dec 31, 2019

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did SIPHA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SIPHA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SIPHA?

Other financial metrics that can be useful for relative valuation.

SIPHA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does SIPHA's PB Ratio compare to its peers?

SIPHA PB Ratio vs Peers
The above table shows the PB ratio for SIPHA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.1x
ADWYA Société ADWYA
3.8x68.0%د.ت128.1m
UMED Unité de Fabrication des Médicaments
2.5x-9.3%د.ت242.9m
524400 Ishita Drugs and Industries
2xn/a₹173.1m
SXTC China SXT Pharmaceuticals
0.1xn/aUS$2.1m
SIPHA Société des Industries Pharmaceutiques de Tunisie -
n/an/aد.ت7.4m

Price-To-Book vs Peers: Insufficient data to calculate SIPHA's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does SIPHA's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

Price-To-Book vs Industry: Insufficient data to calculate SIPHA's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is SIPHA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SIPHA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SIPHA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SIPHA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SIPHA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SIPHA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of SIPHA's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Future Growth

How is Société des Industries Pharmaceutiques de Tunisie - forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


7.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Société des Industries Pharmaceutiques de Tunisie - has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of SIPHA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Société des Industries Pharmaceutiques de Tunisie - performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


7.7%

Historical Pharmaceuticals & Biotech annual earnings growth

Earnings and Revenue History

Quality Earnings: Insufficient data to determine if SIPHA has high quality earnings.

Growing Profit Margin: Insufficient data to determine if SIPHA's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SIPHA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare SIPHA's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if SIPHA's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: SIPHA has a negative Return on Equity (0%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Société des Industries Pharmaceutiques de Tunisie -'s financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Société des Industries Pharmaceutiques de Tunisie -'s finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Société des Industries Pharmaceutiques de Tunisie - has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Discover healthy companies

  • Take a look at our analysis of SIPHA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Société des Industries Pharmaceutiques de Tunisie -'s financial data was last updated here.

Dividend

What is Société des Industries Pharmaceutiques de Tunisie - current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Société des Industries Pharmaceutiques de Tunisie - Dividend Yield vs Market
How does Société des Industries Pharmaceutiques de Tunisie - dividend yield compare to the market?
SegmentDividend Yield
Company (Société des Industries Pharmaceutiques de Tunisie -)n/a
Market Bottom 25% (TN)3.4%
Market Top 25% (TN)6.2%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast in 3 Years (Société des Industries Pharmaceutiques de Tunisie -)n/a

Notable Dividend: Unable to evaluate SIPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SIPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIPHA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIPHA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SIPHA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Anis Klouz

3.25yrs

Tenure

Mr. Anis Klouz is Chief Executive Officer of Société des Industries Pharmaceutiques de Tunisie - S.A. from June 26, 2019.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of SIPHA?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

Société des Industries Pharmaceutiques de Tunisie - S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Société des Industries Pharmaceutiques de Tunisie - S.A.
  • Ticker: SIPHA
  • Exchange: BVMT
  • Founded: 1970
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: د.ت7.398m
  • Shares outstanding: 1.80m
  • Website: https://www.siphat.rns.tn

Location

  • Société des Industries Pharmaceutiques de Tunisie - S.A.
  • Fondouk Choucha
  • Ben Arous
  • 2013
  • Tunisia


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIPHABVMT (Bourse des Valeurs Mobilieres)YesShare CapitalTNTNDMay 2001

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/15 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.